Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Joshua Kazam
Age : 45
Public asset : 4,716,825 USD
Country of residence : Unknown
Linked companies : Allogene Therapeutics, Inc. - Screaming Eagle Acquisition Corp. - Kronos Bio, Inc. - Tishman Speyer Innovation Corp. II

Biography of Joshua Kazam 
Mr. Joshua A. Kazam is an Independent Director at Soaring Eagle Acquisition Corp., an Independent Director at Tishman Speyer Innovation Corp. II, an Independent Director at TS Innovation Acquisitions Corp., a Director & Partner at Vida Ventures LLC, a Partner at Two River Consulting LLC, a Director & Co-Owner at Riverbank Capital Securities, Inc., a Co-Founder & Partner at Two River Group Holdings LLC, a Co-Founder at VV Manager LLC, a Director & Vice President at Two River Group Management LLC, a Member-Executive Board at The Wharton School of the University of Pennsylvania and a Principal at BCIF Pty Ltd. He is on the Board of Directors at Soaring Eagle Acquisition Corp., Tishman Speyer Innovation Corp. II, TS Innovation Acquisitions Corp., Breakthrough Properties LLC, Breakthrough Services LLC, Allogene Therapeutics, Inc., Vida Ventures LLC, Kronos Bio, Inc., ByHeart, Inc., Desert Flower Foundation GmbH, Vision Path, Inc., MedPod, Inc., Veterinary Prime, Inc., Riverbank Capital Securities, Inc., 105 W First Street LLC, Cortiva Therapy, Danube Pharmaceuticals, Inc., Kirax Corp., Tranzutary Holdings LLC, Vetprime, Inc. and Two River Group Management LLC. Mr. Kazam was previously employed as an Independent Director by Flying Eagle Acquisition Corp., an Independent Director by Diamond Eagle Acquisition Corp., an Independent Director by Platinum Eagle Acquisition Corp., an Independent Director by Capricor Therapeutics, Inc., a Director-Investment Management by Orion Biomedical Fund LP, a Managing Director by Paramount BioCapital, Inc., and a Chief Executive Officer & Director by IconOVir Bio, Inc. He also served on the board at Kite Pharma, Inc., Velcera, Inc., Arno Therapeutics, Inc., Nile Therapeutics, Inc. /Old/, Arno Therapeutics, Inc. /Old/, Manhattan Pharmaceuticals, Inc. and Velcera Pharmaceuticals, Inc. /Old/. He received his undergraduate degree from The Wharton School of the University of Pennsylvania.


Current positions of Joshua Kazam 
Holdings of Joshua Kazam 
Joshua Kazam : Personal Network 
Most Read News 
01/18ELON MUSK : Tesla investors urge judge to order Musk repay $13 billion for SolarCity deal
RE
01/11JAMIE DIMON : JPMorgan's Dimon says consumer loan growth may take 6-9 months to return to normal
RE
01/13JACK DORSEY : Jack Dorsey's Block to build an open bitcoin mining system
RE
01/14ELON MUSK : Musk says Tesla to accept dogecoin for merchandise
RE
01/10BRUNELLO CUCINELLI : Luxury group Cucinelli posts 31% sales jump in 2021
RE
01/11CATHIE WOOD : ARK's Wood turns focus to deflation, 'stay connected' stocks
RE
01/12MARTIN SORRELL : Sorrell's S4 says trading well ahead of guidance
RE
01/13AMANCIO ORTEGA : Inditex founder Amancio Ortega buys Toronto's Royal Bank Plaza for $916 mln
RE
01/07RICHARD BRANSON : British tycoon Branson to list blank-check firm in Amsterdam, Sky News says
RE
01/17ELON MUSK : Top Energy News of the Day
DJ
More news


© 2022 People and Ownership :   
Joshua Kazam : Connections 


Latest news about Joshua Kazam 
01/10Screaming Eagle Acquisition Corp. Announces Executive Appointments
CI
2021Soaring Eagle Acquisition Corp. Announces Board and Committee Appointments
CI
2021Tishman Speyer Innovation Corp. II Announces Board and Committee Changes
CI
2020TS Innovation Acquisitions Corp. Announces Board Appointments
CI
2020Flying Eagle Acquisition Corp. Announces Board Changes; Adopts Second Amended and Restated Certificate of Incorporation
CI
2019Diamond Eagle Acquisition Corp. Announces Executive Changes
CI
2018Allogene Therapeutics, Inc. Announces Board of Directors
CI
More news